abrdn Life Sciences Investors (NYSE:HQL) Hits New 52-Week High – Should You Buy?

abrdn Life Sciences Investors (NYSE:HQL)’s stock price reached a new 52-week high during trading on Monday . The company traded as high as $19.63 and last traded at $19.4820, with a volume of 39963 shares trading hands. The stock had previously closed at $19.25.

abrdn Life Sciences Investors Stock Up 1.5%

The business has a fifty day moving average of $17.75 and a two-hundred day moving average of $17.16.

abrdn Life Sciences Investors Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Thursday, May 21st were given a $0.56 dividend. The ex-dividend date was Thursday, May 21st. This represents a $2.24 dividend on an annualized basis and a dividend yield of 11.2%.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Geneos Wealth Management Inc. grew its stake in abrdn Life Sciences Investors by 200.1% in the 2nd quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock valued at $29,000 after acquiring an additional 1,529 shares during the period. Global Retirement Partners LLC increased its holdings in abrdn Life Sciences Investors by 187.8% in the 4th quarter. Global Retirement Partners LLC now owns 7,039 shares of the company’s stock worth $118,000 after acquiring an additional 4,593 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in abrdn Life Sciences Investors during the fourth quarter worth $177,000. Evolve Private Wealth LLC acquired a new position in abrdn Life Sciences Investors during the fourth quarter worth $199,000. Finally, Independent Financial Group LLC acquired a new position in abrdn Life Sciences Investors during the first quarter worth $211,000. 32.21% of the stock is owned by institutional investors and hedge funds.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.